PSMA-ligand PET results | N (%) |
---|---|
Number of PSMA-ligand positive lesions | 185 (100 |
Total number of LNs | 128 (69.2) |
Iliac LNs | 67 (36.2) |
Obturator LNs | 6 (3.2) |
Perirectal LNs | 4 (2.2) |
Periaortic/interaortocaval LNs | 51 (27.6) |
Total number of bone metastases | 45 (24.3) |
Pelvic bone | 24 (13.0) |
Spinal bone | 10 (5.4) |
Other | 11 (5.9) |
Number of visceral metastases | 12 (6.5) |
Concurrent ADT at radiotherapy | 13 (16.7) |
Radiotherapy of metastases | N (%) |
Radiotherapy of LNs | 128 (100) |
CF-RT | 95 (74.2) |
SBRT | 5 (3.9) |
CF-RT plus SBRT | 15 (11.7) |
CF-RT with SIB | 13 (10.2) |
Median dose, EQD2/1.5 Gy (range) | 50.9 (50.0–76.1) |
N (%) | |
Radiotherapy of bone metastases | 45 (100%) |
CF-RT | 26 (57.8) |
SBRT | 15 (33.3) |
CF-RT plus SBRT | 0 (0) |
CF-RT with SIB | 4 (8.9) |
Median dose, EQD2/1.5 Gy (range) | 51.4 (46.4–108.8 |
N (%) | |
Radiotherapy of visceral metastases | 12 (100) |
CF-RT | 8 (66.7) |
SBRT | 4 (33.3) |
CF-RT plus SBRT | 0 |
CF-RT with SIB | 0 |
Median dose, EQD2/1.5 Gy (range) | 64.7 (57.8–85.0) |